+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Somatic augmentation strategies in clozapine resistance--what facts?

Somatic augmentation strategies in clozapine resistance--what facts?

Clinical Neuropharmacology 29(1): 34-44

Polypharmacy without evidence-based support is sometimes needed for patients treated with 40% to 70% clozapine who are clozapine nonresponders. Several somatic augmentation strategies are proposed in the scientific literature, with different levels of evidence for safety and efficacy. The purpose of the present study is to review the available literature on the efficacy and safety of clozapine augmentation with somatic agents other than antipsychotics. The following classes of agents are considered: (1) mood stabilizers, (2) antidepressants, (3) electroconvulsive therapy and repetitive transcranial magnetic stimulation, (4) glutamatergic agents, (5)fatty acids supplements, and (6) benzodiazepines. Case controls and small-size clinical trials largely dominate the literature, limiting the power to draw conclusions concerning safety issues and the meaning of negative studies. Moreover, variable definitions of clozapine resistance, heterogeneous outcome measures, and short duration of treatment trials are additional limitations. Generally, adjunctive strategies for clozapine-resistant patients remain based on scarce evidence of efficacy and significant safety concerns. Low-frequency repetitive transcranial magnetic stimulation, fatty acids supplements, and mirtazapine showed good tolerability and some efficacy, but the results need replication.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 050337933

Download citation: RISBibTeXText

PMID: 16518133

DOI: 10.1097/00002826-200601000-00010

Related references

Clozapine augmentation strategies - a systematic meta-review of available evidence. Treatment options for clozapine resistance. Journal of Psychopharmacology 33(4): 423-435, 2019

Clozapine resistance: augmentation strategies. European Neuropsychopharmacology 22(3): 165-182, 2012

Clozapine resistance--augmentation strategies. European Neuropsychopharmacology 23(4): 338, 2013

Clozapine resistan Augmentation strategies. 2011

When symptoms persist: Clozapine augmentation strategies. Schizophrenia Bulletin 27(4): 615-628, 2001

Augmentation strategies in clozapine-resistant schizophrenia. Cns Drugs 19(10): 843-872, 2005

Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clinical Neuropharmacology 29(1): 28-33, 2006

Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis. Pharmacopsychiatry 47(7): 231-238, 2015

Augmentation strategies in patients with schizophrenia who show partial response to clozapine treatment. Turk Psikiyatri Dergisi 25(3): 201-211, 2014

Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis. Australian and new Zealand Journal of Psychiatry 52(8): 751-767, 2018

Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine. Expert Opinion on PharmacoTherapy 15(16): 2329-2345, 2014

Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophrenia Bulletin 38(5): 1003-1011, 2012

Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders. Journal of Psychopharmacology 30(5): 436-443, 2016

Augmentation of clozapine with valproic Acid for clozapine-induced obsessive-compulsive symptoms. Pharmacopsychiatry 40(5): 202-203, 2007

ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials. Journal of Psychiatric Research 105: 23-32, 2018